Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Hsiao Ching Chuang"'
Autor:
Su-Lin Lee, Chih-Chien Chou, Hsiao-Ching Chuang, En-Chi Hsu, Po-Chen Chiu, Samuel K Kulp, John C Byrd, Ching-Shih Chen
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67149 (2013)
Although the rictor-mTOR complex (mTORC2) has been shown to act as phosphoinositide-dependent kinase (PDK)2 in many cell types, other kinases have also been implicated in mediating Ser473-Akt phosphorylation. Here, we demonstrated the cell line speci
Externí odkaz:
https://doaj.org/article/b2c8fdea46454f19ba16c77a553e7492
Autor:
Min-Wu Chao, Po-Chen Chu, Hsiao-Ching Chuang, Fang-Hsiu Shen, Chih-Chien Chou, En-Chi Hsu, Lauren E. Himmel, Han-Li Huang, Huang-Ju Tu, Samuel K. Kulp, Che-Ming Teng, Ching-Shih Chen
Publikováno v:
Oncotarget
Here, we report a novel non-epigenetic function of histone deacetylase (HDAC) 8 in activating cancer stem cell (CSC)-like properties in breast cancer cells by enhancing the stability of Notch1 protein. The pan-HDAC inhibitors AR-42 and SAHA, and the
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e47298 (2012)
Substantial evidence supports the oncogenic role of the E3 ubiquitin ligase S-phase kinase-associated protein 2 (Skp2) in many types of cancers through its ability to target a broad range of signaling effectors for ubiquitination. Thus, this oncogeni
Externí odkaz:
https://doaj.org/article/fb261384b1ab4fb8bf57b413a1d80acc
Publikováno v:
Pharmacological Research. 117:370-376
The clear importance of mutated KRAS as a therapeutic target has driven the investigation of multiple approaches to inhibit oncogenic KRAS signaling at different molecular levels. However, no KRAS-targeted therapy has reached the clinic to date, whic
Publikováno v:
Current Pharmaceutical Design. 20:2607-2618
Adenosine monophosphate-activated protein kinase (AMPK) is a key player in maintaining energy homeostasis in response to metabolic stress. Beyond diabetes and metabolic syndrome, there is a growing interest in the therapeutic exploitation of the AMPK
Publikováno v:
Journal of Biological Chemistry. 287:43639-43650
The mRNA-stabilizing protein HuR acts a stress response protein whose function and/or protein stability are modulated by diverse stress stimuli through posttranslational modifications. Here, we report a novel mechanism by which metabolic stress facil
Autor:
Samuel K. Kulp, Hao Yu Hsieh, Hsiao Ching Chuang, Dasheng Wang, Shu-Chuan Weng, Po Hsien Huang, Ching-Shih Chen
Publikováno v:
Journal of Medicinal Chemistry. 52:5642-5648
This study is aimed at the pharmacological exploitation of alpha-tocopheryl succinate (1) to develop potent antiadhesion agents. Considering the structural cooperativity between the phytyl chain and the carboxylic terminus in determining the antiadhe
Publikováno v:
Carcinogenesis. 30:1125-1131
As part of our effort to understand the mechanism underlying alpha-tocopheryl succinate [vitamin E succinate (VES)]-mediated antitumor effects, we investigated the signaling pathway by which VES suppresses androgen receptor (AR) expression in prostat
Autor:
Samuel K. Kulp, Wan-Chi Tsai, Andrew J. Paterson, Hsiao-Ching Chuang, Shuo Wei, Ching-Shih Chen, Hsiao-Ching Yang, Shiuh-Rong Ho
Publikováno v:
Molecular Pharmacology. 76:47-57
This study investigated the mechanism by which the transcription factor Sp1 is degraded in prostate cancer cells. We recently developed a thiazolidinedione derivative, (Z)-5-(4-hydroxy-3-trifluoromethylbenzylidene)-3-(1-methylcyclohexyl)-thiazolidine
Autor:
Samuel K. Kulp, Hsiao-Ching Yang, Ching-Shih Chen, Pei Jung Lu, Shuo Wei, Jian Yang, Ming Derg Lai, Hsiao Ching Chuang
Publikováno v:
Journal of Biological Chemistry. 283:26759-26770
This study identifies a novel mechanism by which thiazolidinediones mediate cyclin D1 repression in prostate cancer cells. Based on the finding that the thiazolidinedione family of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists